newsfilter
← Latest News
GlobeNewswire·

X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

- 4WARD Phase 3 Chronic Neutropenia Trial Expected to Achieve Target Enrollment in Q4 2026 - - Initiating 4STEPS Phase 2b Trial Evaluating G-CSF Dose Reduction with Mavorixafor; Enrollment of First Participant Expected